Findings

What do systematic reviews say?

16 questions · 16 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 12.5%GRADE not reported 0 · 0%Very low 6 · 37.5%Low 7 · 43.8%Moderate 1 · 6.3%High 0 · 0%

GLP‐1 agonists vs placebo

HbA1c (%) · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 283 participants
Moderate

GLP‐1 agonists vs placebo

FBG (mmol/L) · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 231 participants
Very low

GLP‐1 agonists vs placebo

Death (all causes) · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 301 participants
Very low

GLP‐1 agonists vs placebo

All cardiovascular death · people with diabetes and CKD

The review found no eligible studies for this question.

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

GLP‐1 agonists vs placebo

Weight (kg) · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 303 participants
Low

GLP‐1 agonists vs placebo

eGFR · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 279 participants
Low

GLP‐1 agonists vs placebo

Hypoglycaemia · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 303 participants
Low

GLP‐1 agonists vs placebo

Discontinuation of medication due to adverse events · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 303 participants
Low

GLP‐1 agonists vs placebo

PD motor impairment · adults with Parkinson's disease

1 finding from 1 review

GLP‐1 receptor agonists for Parkinson's disease 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 60 participants
Low

GLP‐1 agonists vs placebo

Health‐related quality of life · adults with Parkinson's disease

1 finding from 1 review

GLP‐1 receptor agonists for Parkinson's disease 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 60 participants
Low

GLP‐1 agonists vs placebo

Serious adverse events · adults with Parkinson's disease

The review found no eligible studies for this question.

1 finding from 1 review

GLP‐1 receptor agonists for Parkinson's disease 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

GLP‐1 agonists vs placebo

Adverse events ‐ weight loss · adults with Parkinson's disease

GLP‐1 receptor agonists showed no clear difference in adverse events ‐ weight loss compared with placebo (low certainty).

1 finding from 1 review

GLP‐1 receptor agonists for Parkinson's disease 2020 · Cochrane Headline outcomes only
RR 1.25 [0.89, 1.76]
1 study · 60 participants
Low

GLP‐1 agonists vs no treatment

PD motor impairment · adults with Parkinson's disease

1 finding from 1 review

GLP‐1 receptor agonists for Parkinson's disease 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 44 participants
Very low

GLP‐1 agonists vs no treatment

Health‐related quality of life · adults with Parkinson's disease

1 finding from 1 review

GLP‐1 receptor agonists for Parkinson's disease 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 44 participants
Very low

GLP‐1 agonists vs no treatment

Serious adverse events. · adults with Parkinson's disease

It is very uncertain whether GLP‐1 receptor agonists changes serious adverse events. compared with no treatment (very low certainty).

1 finding from 1 review

GLP‐1 receptor agonists for Parkinson's disease 2020 · Cochrane Headline outcomes only
RR 1.6 [0.4, 6.32]
1 study · 44 participants
Very low

GLP‐1 agonists vs no treatment

Adverse events ‐ weight loss · adults with Parkinson's disease

1 finding from 1 review

GLP‐1 receptor agonists for Parkinson's disease 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 44 participants
Very low